|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data suggest that the goal to use SGLT2 inhibitors for their vasculo- and renoprotective actions may be problematic, as those most likely to benefit may also have the highest risk for DKA.
|
31529090 |
2020 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although well tolerated, there are known adverse effects with SGLT2 inhibitors that require clinical monitoring, such as genital mycotic infections, diabetic ketoacidosis, volume depletion particularly in the setting of concomitant diuretic use, and lower limb amputations with canagliflozin.
|
31494110 |
2020 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Melatonin ameliorates SGLT2 inhibitor-induced diabetic ketoacidosis by inhibiting lipolysis and hepatic ketogenesis in type 2 diabetic mice.
|
31743484 |
2020 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
More DKA events were observed during off-label use of SGLT2 inhibitors in Sentinel than would be expected based on sotagliflozin clinical trials (SIR = 1.83; 95% CI, 1.45-2.28).
|
31601640 |
2020 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
SGLT2 inhibitors induced a higher risk for DKA than metformin/placebo.
|
31694774 |
2020 |
|
Diabetic Ketoacidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
They have carried out a metanalysis showing a 3.5-fold increase in the risk of diabetic ketoacidosis (DKA) in patients with type 1 diabetes under treatment with SGLT2 inhibitors.
|
31334593 |
2019 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Several other SGLT2 inhibitors have been associated with increased frequency of diabetic ketoacidosis (DKA).
|
30880915 |
2019 |
|
Diabetic Ketoacidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Diabetic ketoacidosis (DKA) has been associated with the use of sodium glucose cotransporter 2 inhibitors (SGLT2is).
|
30835263 |
2019 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
When compared with placebo, SGLT2 inhibitors were found to be significantly protective against AKI (RR=0.59; 95% CI 0.39 to 0.89; I<sup>2</sup>=0.0%), while no difference was found for DKA (RR 0.66; 95% CI 0.30 to 1.45, I<sup>2</sup>=0.0%), UTI (RR 1.02; 95% CI 0.95 to 1.09, I<sup>2</sup>=0.0%) or bone fracture (RR 0.87; 95% CI 0.69 to 1.09, I<sup>2</sup>=1.3%).
|
30813108 |
2019 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
SGLT2 inhibitors in high and moderate doses can achieve a better outcome on efficacy, but may induce a higher risk of adverse events, especially DKA.
|
30565398 |
2019 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Adverse Drug Reaction Profile of SGLT2 Inhibitor-Associated Diabetic Ketosis/Ketoacidosis in Singapore and their Precipitating Factors.
|
31065934 |
2019 |
|
Diabetic Ketoacidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Adverse events including diabetic ketoacidosis in post-bariatric patients on sodium-glucose co-transporter 2 (SGLT2) inhibitors or inadequate insulin have been reported in patient's with both type 1 and type 2 diabetes.
|
31686263 |
2019 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Diabetic ketoacidosis occurred more often with SGLT-2 inhibitors and SGLT-1/2 inhibitors vs placebo, although the incidence was generally low.
|
31081593 |
2019 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
We report a novel complication of hypoglycemia that occurred during the course of treatment of SGLT2 inhibitor-induced DKA in a patient with type 2 diabetes mellitus (T2DM) on the dapagliflozin-metformin combination.
|
31489272 |
2019 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Based on their history of medications taken before admission, subjects were classified as either users or non-users of SGLT2 inhibitors and their clinical characteristics of DKA were compared.
|
30639566 |
2019 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, SGLT2 inhibitor therapy induces serious adverse events, including a roughly six-times increased risk of diabetic ketoacidosis.
|
31585721 |
2019 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
It is important for emergency physicians to be aware of this phenomenon in all SGLT2-inhibitor users, as a delay in the diagnosis of DKA can be life threatening.
|
29157798 |
2018 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
There was no significant increase in the rate of hypoglycaemia or severe hypoglycaemia; however, SGLT2 inhibitor therapy increased diabetic ketoacidosis (odds ratio [OR] 3.38) and genital tract infection (OR 3.44).
|
29451721 |
2018 |
|
Diabetic Ketoacidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Increased risk of diabetic ketoacidosis (DKA) with uncharacteristically mild-to-moderate glucose elevations (euglycemic DKA) is associated with the use of all the approved SGLT2 inhibitors.
|
29916741 |
2018 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
When insulin dosage is lowered too much, SGLT2 inhibitors can enhance ketogenesis to the extent that the risk of diabetic ketoacidosis increases, particularly in type 1 diabetic patients.
|
29663292 |
2018 |
|
Diabetic Ketoacidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We found that SGLT2 inhibitor treatment did not increase the risk of DKA compared with DPP-4 inhibitor treatment.
|
29569427 |
2018 |
|
Diabetic Ketoacidosis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Agents in the sodium glucose co-transporter-2 inhibitor (SGLT-2) class demonstrate the greatest promise in correcting hyperglycaemia, but there are safety concerns in relation to the risk of diabetic ketoacidosis.
|
30209797 |
2018 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The total incidence of adverse events (AEs), hypoglycemia, and genital and urinary infections were also similar to placebo, while an increased incidence of diabetic ketoacidosis (DKA) (n = 16) was seen in SGLT-2 inhibitors group.
|
28276512 |
2017 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Effects of SGLT-2 inhibitors on diabetic ketoacidosis: A meta-analysis of randomised controlled trials.
|
28570924 |
2017 |
|
Diabetic Ketoacidosis
|
0.100 |
Biomarker
|
disease |
BEFREE |
SGLT2 inhibitors and diabetic ketoacidosis: data from the FDA Adverse Event Reporting System.
|
28500396 |
2017 |